198 related articles for article (PubMed ID: 36073513)
21. RUNX1 is required for oncogenic
Choi A; Illendula A; Pulikkan JA; Roderick JE; Tesell J; Yu J; Hermance N; Zhu LJ; Castilla LH; Bushweller JH; Kelliher MA
Blood; 2017 Oct; 130(15):1722-1733. PubMed ID: 28790107
[TBL] [Abstract][Full Text] [Related]
22. Notch1 inhibition targets the leukemia-initiating cells in a Tal1/Lmo2 mouse model of T-ALL.
Tatarek J; Cullion K; Ashworth T; Gerstein R; Aster JC; Kelliher MA
Blood; 2011 Aug; 118(6):1579-90. PubMed ID: 21670468
[TBL] [Abstract][Full Text] [Related]
23. ARID5B as a critical downstream target of the TAL1 complex that activates the oncogenic transcriptional program and promotes T-cell leukemogenesis.
Leong WZ; Tan SH; Ngoc PCT; Amanda S; Yam AWY; Liau WS; Gong Z; Lawton LN; Tenen DG; Sanda T
Genes Dev; 2017 Dec; 31(23-24):2343-2360. PubMed ID: 29326336
[TBL] [Abstract][Full Text] [Related]
24. Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levels.
Bressanin D; Evangelisti C; Ricci F; Tabellini G; Chiarini F; Tazzari PL; Melchionda F; Buontempo F; Pagliaro P; Pession A; McCubrey JA; Martelli AM
Oncotarget; 2012 Aug; 3(8):811-23. PubMed ID: 22885370
[TBL] [Abstract][Full Text] [Related]
25. microRNAs regulate TAL1 expression in T-cell acute lymphoblastic leukemia.
Correia NC; Melão A; Póvoa V; Sarmento L; Gómez de Cedrón M; Malumbres M; Enguita FJ; Barata JT
Oncotarget; 2016 Feb; 7(7):8268-81. PubMed ID: 26882564
[TBL] [Abstract][Full Text] [Related]
26. Defining the molecular basis of oncogenic cooperation between TAL1 expression and Pten deletion in T-ALL using a novel pro-T-cell model system.
Bornschein S; Demeyer S; Stirparo R; Gielen O; Vicente C; Geerdens E; Ghesquière B; Aerts S; Cools J; de Bock CE
Leukemia; 2018 Apr; 32(4):941-951. PubMed ID: 29151585
[TBL] [Abstract][Full Text] [Related]
27. LINC00665 promotes the viability, migration and invasion of T cell acute lymphoblastic leukemia cells by targeting miR-101 via modulating PI3K/Akt pathway.
Abuduer M; A EZG
Tissue Cell; 2021 Aug; 71():101579. PubMed ID: 34171521
[TBL] [Abstract][Full Text] [Related]
28. MicroRNA-193b-3p acts as a tumor suppressor by targeting the MYB oncogene in T-cell acute lymphoblastic leukemia.
Mets E; Van der Meulen J; Van Peer G; Boice M; Mestdagh P; Van de Walle I; Lammens T; Goossens S; De Moerloose B; Benoit Y; Van Roy N; Clappier E; Poppe B; Vandesompele J; Wendel HG; Taghon T; Rondou P; Soulier J; Van Vlierberghe P; Speleman F
Leukemia; 2015 Apr; 29(4):798-806. PubMed ID: 25231743
[TBL] [Abstract][Full Text] [Related]
29. ERG promotes T-acute lymphoblastic leukemia and is transcriptionally regulated in leukemic cells by a stem cell enhancer.
Thoms JA; Birger Y; Foster S; Knezevic K; Kirschenbaum Y; Chandrakanthan V; Jonquieres G; Spensberger D; Wong JW; Oram SH; Kinston SJ; Groner Y; Lock R; MacKenzie KL; Göttgens B; Izraeli S; Pimanda JE
Blood; 2011 Jun; 117(26):7079-89. PubMed ID: 21536859
[TBL] [Abstract][Full Text] [Related]
30. Targeting signaling pathways in T-cell acute lymphoblastic leukemia initiating cells.
Martelli AM; Lonetti A; Buontempo F; Ricci F; Tazzari PL; Evangelisti C; Bressanin D; Cappellini A; Orsini E; Chiarini F
Adv Biol Regul; 2014 Sep; 56():6-21. PubMed ID: 24819383
[TBL] [Abstract][Full Text] [Related]
31. IL7R overexpression in adult acute lymphoblastic leukemia is associated to JAK/STAT pathway mutations and identifies patients who could benefit from targeted therapies.
Gianfelici V; Messina M; Paoloni F; Peragine N; Lauretti A; Fedullo AL; Di Giacomo F; Vignetti M; Vitale A; Guarini A; Chiaretti S; Foà R
Leuk Lymphoma; 2019 Mar; 60(3):829-832. PubMed ID: 30188230
[No Abstract] [Full Text] [Related]
32. Dynamic interaction between TAL1 oncoprotein and LSD1 regulates TAL1 function in hematopoiesis and leukemogenesis.
Li Y; Deng C; Hu X; Patel B; Fu X; Qiu Y; Brand M; Zhao K; Huang S
Oncogene; 2012 Nov; 31(48):5007-18. PubMed ID: 22310283
[TBL] [Abstract][Full Text] [Related]
33. SIX6 is a TAL1-regulated transcription factor in T-ALL and associated with inferior outcome.
Laukkanen S; Oksa L; Nikkilä A; Lahnalampi M; Parikka M; Seki M; Takita J; Degerman S; de Bock CE; Heinäniemi M; Lohi O
Leuk Lymphoma; 2020 Dec; 61(13):3089-3100. PubMed ID: 32835548
[TBL] [Abstract][Full Text] [Related]
34. Monoallelic
Veiga DFT; Tremblay M; Gerby B; Herblot S; Haman A; Gendron P; Lemieux S; Zúñiga-Pflücker JC; Hébert J; Cohen JP; Hoang T
Front Immunol; 2022; 13():867443. PubMed ID: 35401501
[TBL] [Abstract][Full Text] [Related]
35. Repressed BMP signaling reactivates NKL homeobox gene MSX1 in a T-ALL subset.
Nagel S; Ehrentraut S; Meyer C; Kaufmann M; Drexler HG; MacLeod RA
Leuk Lymphoma; 2015 Feb; 56(2):480-91. PubMed ID: 24844359
[TBL] [Abstract][Full Text] [Related]
36. Requirement for Lyl1 in a model of Lmo2-driven early T-cell precursor ALL.
McCormack MP; Shields BJ; Jackson JT; Nasa C; Shi W; Slater NJ; Tremblay CS; Rabbitts TH; Curtis DJ
Blood; 2013 Sep; 122(12):2093-103. PubMed ID: 23926305
[TBL] [Abstract][Full Text] [Related]
37. Novel Compound, ND-17, Regulates the JAK/STAT, PI3K/AKT, and MAPK Pathways and Restrains Human T-lymphoid Leukemia Development.
Ma W; Liu Y; Lei P; Zhu M; Pan X
Curr Cancer Drug Targets; 2022; 22(5):404-413. PubMed ID: 35249489
[TBL] [Abstract][Full Text] [Related]
38. Transcriptional regulatory networks downstream of TAL1/SCL in T-cell acute lymphoblastic leukemia.
Palomero T; Odom DT; O'Neil J; Ferrando AA; Margolin A; Neuberg DS; Winter SS; Larson RS; Li W; Liu XS; Young RA; Look AT
Blood; 2006 Aug; 108(3):986-92. PubMed ID: 16621969
[TBL] [Abstract][Full Text] [Related]
39. Alteration of CTCF-associated chromatin neighborhood inhibits TAL1-driven oncogenic transcription program and leukemogenesis.
Li Y; Liao Z; Luo H; Benyoucef A; Kang Y; Lai Q; Dovat S; Miller B; Chepelev I; Li Y; Zhao K; Brand M; Huang S
Nucleic Acids Res; 2020 Apr; 48(6):3119-3133. PubMed ID: 32086528
[TBL] [Abstract][Full Text] [Related]
40. Single-cell profiling of pediatric T-cell acute lymphoblastic leukemia: Impact of PTEN exon 7 mutation on PI3K/Akt and JAK-STAT signaling pathways.
Bonaccorso P; Bugarin C; Buracchi C; Fazio G; Biondi A; Lo Nigro L; Gaipa G
Cytometry B Clin Cytom; 2020 Nov; 98(6):491-503. PubMed ID: 32479694
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
